Cencora, Inc. $COR Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund decreased its position in shares of Cencora, Inc. (NYSE:COR) by 1.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 137,371 shares of the company’s stock after selling 2,600 shares during the quarter. New York State Common Retirement Fund owned about 0.07% of Cencora worth $42,933,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Atlantic Edge Private Wealth Management LLC grew its position in Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after purchasing an additional 35 shares during the last quarter. Vermillion & White Wealth Management Group LLC boosted its position in shares of Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after buying an additional 43 shares during the period. Copia Wealth Management grew its holdings in Cencora by 505.0% in the 3rd quarter. Copia Wealth Management now owns 121 shares of the company’s stock worth $38,000 after buying an additional 101 shares in the last quarter. Caldwell Trust Co bought a new position in Cencora in the 2nd quarter worth approximately $46,000. Finally, Salomon & Ludwin LLC increased its position in Cencora by 638.1% in the 3rd quarter. Salomon & Ludwin LLC now owns 155 shares of the company’s stock valued at $47,000 after acquiring an additional 134 shares during the period. Institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Shares of Cencora stock opened at $359.14 on Friday. Cencora, Inc. has a 52 week low of $237.71 and a 52 week high of $377.54. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. The stock has a market cap of $69.67 billion, a PE ratio of 45.17, a price-to-earnings-growth ratio of 1.68 and a beta of 0.66. The company’s 50-day moving average price is $347.62 and its two-hundred day moving average price is $323.87.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same quarter last year, the firm posted $3.34 EPS. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were issued a $0.60 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s dividend payout ratio is currently 30.19%.

Insider Activity

In other news, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the sale, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the sale, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. This represents a 7.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 20,316 shares of company stock worth $7,151,265. Insiders own 0.38% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. UBS Group increased their price target on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Wells Fargo & Company upped their price objective on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Barclays initiated coverage on shares of Cencora in a research report on Monday, December 8th. They issued an “overweight” rating and a $400.00 target price for the company. Evercore ISI set a $400.00 price target on shares of Cencora and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Cencora in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $393.08.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.